Resistance to c-Kit inhibitors in melanoma: Insights for future therapies

Oncoscience

Volumn 1, Issue 6, 2014, Pages 423-426

  Carlino, Matteo S ^a,b,c   Todd, Jason R ^a,d   Rizos, Helen ^a,b,e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b BLACKTOWN HOSPITAL   (Australia)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e MACQUARIE UNIVERSITY   (Australia)

Author keywords

C Kit; MAPK; PI3K

Indexed keywords

EID: 84931057374     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.51     Document Type: Article

References (27)

1. Curtin JA, Busam K, Pinkel D and Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006; 24(26): 4340-4346.
2. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, Fletcher CD, Demetri GD and Fletcher JA. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 2004; 23(22): 3999-4006.
3. Miettinen M and Lasota J. Gastrointestinal stromal tumors definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv: an international journal of pathology. 2001; 438(1): 1-12.
4. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CDM, Roberts PJ, Heinz D, Wehre E, Nikolova Z and Joensuu H. Long-Term Results From a Randomized Phase II Trial of Standard-Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT. Journal of Clinical Oncology. 2008; 26(4): 620-625.
5. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011; 305(22): 2327-2334.
6. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011; 29(21): 2904-2909.
7. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, et al. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. Journal of Clinical Oncology. 2013; 31(26): 3182-3190.
8. Mar VJ, Wong SQ, Li J, Scolyer RA, McLean C, Papenfuss AT, Tothill RW, Kakavand H, Mann GJ, Thompson JF, Behren A, Cebon JS, Wolfe R, Kelly JW, Dobrovic A and McArthur GA. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res. 2013; 19(17): 4589-4598.
9. Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O and Bastian BC. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res. 2012; 18(5): 1457-1463.
10. Conca E, Negri T, Gronchi A, Fumagalli E, Tamborini E, Pavan GM, Fermeglia M, Pierotti Ma, Pricl S and Pilotti S. Activate and resist: L576P-KIT in GIST. Mol Cancer Ther. 2009; 8(9): 2491-2495.
11. Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A and Sznol M. A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011; 117(10): 2202-2208.
12. Cho JH, Kim KM, Kwon M, Kim JH and Lee J. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Investigational new drugs. 2012; 30(5): 2008-2014.
13. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JMG, Utikal J, Dreno B, Nyakas M, et al. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine. 2012; 367(2): 107-114.
14. Todd JR, Scurr LL, Becker TM, Kefford RF and Rizos H. The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. Oncogene. 2014; 33(2): 236-245.
15. Todd JR, Becker TM, Kefford RF and Rizos H. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells. Pigment Cell Melanoma Res. 2013; 26(4): 518-526.
16. Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, Heinicke T, Speidel N, Pietsch T, Buettner R, Pink D, Reichardt P and Hohenberger P. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006; 12(6): 1743-1749.
17. Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, Fletcher CD, Corless CL and Fletcher JA. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. The Journal of pathology. 2008; 216(1): 64-74.
18. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM and Demetri GD. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008; 26(33): 5352-5359.
19. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Robyn S, Thompson JF, Kefford RF, Scolyer RA and Long GV. BRAF inhibitor resistance mechanisms in metastatic melanoma; spectrum and clinical impact. Clin Cancer Res. 2014; 20(7): 1965-77.
20. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, et al. Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discov. 2014; 4(1): 80-93.
21. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P and Scolyer RA. Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma. Clinical Cancer Research. 2012; 18(5): 1386-1394.
22. Zitvogel L and Kroemer G. Anticancer effects of imatinib via immunostimulation. Nat Med. 2011; 17(9): 1050-1051.
23. Yang Y, Liu C, Peng W, Lizee G, Overwijk WW, Liu Y, Woodman SE and Hwu P. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 2012; 120(23): 4533-4543.
24. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizee G, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013; 19(5): 1225-1231.
25. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT and Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Science translational medicine. 2013; 5(200): 200ra116.
26. Lyle M and Long GV. Diagnosis and Treatment of KITMutant Metastatic Melanoma. Journal of Clinical Oncology. 2013; 31(26): 3176-3181.
27. Ott PA, Hodi FS and Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013; 19(19): 5300-5309.